Subcutaneous formulation of XBiotech's bermekimab successful in mid-stage study
… trial evaluating a subcutaneous formulation of XBiotech's (NASDAQ:XBIT) bermekimab in patients with moderate-to-severe hidradenitis suppurativa …
Blog - Latest News
You are here: Home / Hidradenitis suppurativa / Subcutaneous formulation of XBiotech's bermekimab successful in mid-stage...
Interesting links
Here are some interesting links for you! Enjoy your stay :)Categories
Archive
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
Leave a Reply
Want to join the discussion?Feel free to contribute!